Subject: FW: Anaphylaxis linked to COVID-19 vaccination - documents
From: Tamar Gabunia </O=EXCHORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=E6CA04F38EC94D0CADAB9CBDF90FCDDE-TAMAR G>
To: "[email-masked]<[email-masked]>" <[email-masked]>, [email-masked]
Date: Thu, 01 Apr 2021 04:01:17 +0000

From: DOMENTE, Silviu [mailto:[email-masked]]
Sent: 26 March, 2021 03:25
To: Tamar Gabunia ; M Géorgie - Ms I. Khonelidze ([email-masked])
Cc: Maia Nikoleishvili
Subject: FW: Anaphylaxis linked to COVID-19 vaccination - documents

FYI

From: DATTA, Siddhartha Sankar <[email-masked]>
Sent: Thursday, March 25, 2021 22:17
To: EU Heads Of COs <[email-masked]>
Cc: BERDZULI, Nino <[email-masked]>; EURO DEC/VPI/RO/P-Staff <[email-masked]>; EURO DEC/VPI/CO/P-Staff <[email-masked]>; EURO2019nCoV <[email-masked]>; EU IMST COVID Leads <[email-masked]>; NIAZYAN, Lyudmila <[email-masked]>; KURTSIKASHVILI, Giorgi <[email-masked]>; GHEORGHITA, Stela <[email-masked]>; SULEYMANOVA, Javahir <[email-masked]>; RANCIC, Miljan <[email-masked]>; PALO, Mirza <[email-masked]>; REBAC, Boris <[email-masked]>; BEJTJA, Gazmend <[email-masked]>; KULI, Arta <[email-masked]>; HUMOLLI, Isme <[email-masked]>; MENGISTU, Abebayehu Assefa <[email-masked]>; ESENAMANOV, Vasily <[email-masked]>; ATATRAH, DR Tasnim <[email-masked]>; SIMONIAN, Guillaume <[email-masked]>; GARNER, Sarah <[email-masked]>; PIRGARI, Dorina <[email-masked]>; EURO WHE COM Focal Points <[email-masked]>; CRAIG, Brett Janson <[email-masked]>
Subject: Anaphylaxis linked to COVID-19 vaccination - documents

Dear WRs/HCOs,

As we have indicated in our email below and after incorporating the inputs from the webinars held recently, please find attached the crisis communication plan for any reported anaphylaxis or death following COVID-19 vaccination. Some reference in the crisis communication document has been made to AstraZeneca vaccine (of immediate relevance) but can also be used for other vaccines.

Also find attached the practical guidance document on identification, case management and response of anaphylaxis in a primary care setting is attached (English and Russian version).

Few points:

-          The reported cases of “adverse events following immunization” by vaccine product will be communicated to the countries as information is received from the global database – and we will keep you posted.

-          As for Q&A, the four webinars we have organized provided a base for the MoH/National Immunization Programme to ask questions. We are in touch with our WHO HQ colleagues, Collaborating Centre and technical specialists on the various aspects raised by the participants on this topic.

We will share these documents with our national counterparts. Glad if you can forward the attached document to relevant authorities.

Thanks,
Siddhartha